Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial

Oza et al. (Wed,) studied this question.

www.synapsesocial.com/papers/69dc3d64d74bf23813c0fc64 — DOI: https://doi.org/10.1016/s1470-2045(15)00086-8

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Late breaking abstracts· 2007 · 44 citations
2. A phase III randomized controlled clinical trial of carboplatin and paclitaxel alone or in combination with bevacizumab followed by bevacizumab and secondary cytoreductive surgery in platinum-sensitive, recurrent ovarian, peritoneal primary and fallopian tube cancer (Gynecologic Oncology Group 0213)· 2015 · 42 citations
3. New Guidelines to Evaluate the Response to Treatment in Solid Tumors· 2000 · 15,703 citations
4. Tumor Angiogenesis: Therapeutic Implications· 1971 · 10,118 citations
5. Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer· 2012 · 243 citations